News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
109,424 Results
Type
Article (4334)
Company Profile (48)
Press Release (105041)
Multimedia
Podcasts (9)
Webinars (3)
Section
Business (34577)
Career Advice (86)
Deals (6554)
Drug Delivery (9)
Drug Development (11966)
Employer Resources (10)
FDA (2227)
Job Trends (1543)
News (55814)
Policy (4527)
Tag
Academia (245)
Accelerated approval (2)
Allergies (22)
Alliances (11263)
ALS (16)
Alzheimer's disease (208)
Antibody-drug conjugate (ADC) (86)
Approvals (2334)
Artificial intelligence (55)
Autoimmune disease (20)
Automation (3)
Bankruptcy (20)
Best Places to Work (1036)
BIOSECURE Act (2)
Biosimilars (77)
Biotechnology (34)
Bladder cancer (35)
Brain cancer (11)
Breast cancer (94)
Cancer (800)
Cardiovascular disease (25)
Career advice (74)
Career pathing (1)
CAR-T (46)
CDC (1)
Cell therapy (131)
Cervical cancer (5)
Clinical research (10574)
Collaboration (426)
Company closure (2)
Compensation (122)
Complete response letters (5)
COVID-19 (367)
CRISPR (11)
C-suite (174)
Cystic fibrosis (13)
Data (978)
Denatured (6)
Depression (22)
Diabetes (46)
Diagnostics (1071)
Digital health (7)
Diversity (2)
Diversity, equity & inclusion (1)
Drug discovery (65)
Drug pricing (11)
Duchenne muscular dystrophy (73)
Earnings (12241)
Editorial (5)
Employer branding (1)
Employer resources (8)
Events (13685)
Executive appointments (189)
FDA (2749)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (1)
Funding (283)
Gene editing (37)
Generative AI (2)
Gene therapy (84)
GLP-1 (120)
Government (390)
Grass and pollen (1)
Guidances (62)
Healthcare (1757)
HIV (3)
Huntington's disease (5)
IgA nephropathy (28)
Immunology and inflammation (36)
Immuno-oncology (17)
Indications (17)
Infectious disease (395)
Inflammatory bowel disease (37)
Inflation Reduction Act (7)
Influenza (19)
Intellectual property (56)
Interviews (7)
IPO (2597)
IRA (7)
Job creations (520)
Job search strategy (70)
JPM (7)
Kidney cancer (6)
Labor market (11)
Layoffs (55)
Leadership (3)
Legal (1155)
Liver cancer (23)
Longevity (1)
Lung cancer (116)
Lymphoma (47)
Machine learning (3)
Management (4)
Manufacturing (132)
MASH (23)
Medical device (1491)
Medtech (1499)
Mergers & acquisitions (4226)
Metabolic disorders (140)
Multiple sclerosis (39)
NASH (1)
Neurodegenerative disease (51)
Neuropsychiatric disorders (16)
Neuroscience (414)
NextGen: Class of 2026 (552)
Non-profit (212)
Now hiring (11)
Obesity (57)
Opinion (18)
Ovarian cancer (40)
Pain (36)
Pancreatic cancer (37)
Parkinson's disease (42)
Partnered (6)
Patents (100)
Patient recruitment (75)
Peanut (2)
People (10486)
Pharmaceutical (7)
Pharmacy benefit managers (4)
Phase 1 (3396)
Phase 2 (4683)
Phase 3 (3622)
Pipeline (959)
Policy (17)
Postmarket research (270)
Preclinical (1299)
Press Release (4)
Prostate cancer (29)
Psychedelics (3)
Radiopharmaceuticals (37)
Rare diseases (121)
Real estate (1031)
Recruiting (5)
Regulatory (3695)
Reports (11)
Research institute (252)
Resumes & cover letters (9)
Rett syndrome (1)
RNA editing (7)
RSV (3)
Schizophrenia (27)
Series A (68)
Series B (44)
Service/supplier (4)
Sickle cell disease (9)
Special edition (3)
Spinal muscular atrophy (7)
Sponsored (4)
Startups (884)
Stomach cancer (3)
Supply chain (15)
Tariffs (2)
The Weekly (3)
Vaccines (90)
Venture capital (22)
Weight loss (26)
Women's health (14)
Worklife (1)
Date
Today (8)
Last 7 days (93)
Last 30 days (354)
Last 365 days (5055)
2026 (585)
2025 (5003)
2024 (5656)
2023 (6496)
2022 (10344)
2021 (10040)
2020 (8750)
2019 (5774)
2018 (4468)
2017 (5222)
2016 (4691)
2015 (5725)
2014 (4303)
2013 (3750)
2012 (4163)
2011 (4249)
2010 (3797)
Location
Africa (128)
Alabama (6)
Arizona (28)
Asia (24030)
Australia (2649)
California (2184)
Canada (607)
China (437)
Colorado (60)
Connecticut (32)
Delaware (11)
Europe (16351)
Florida (120)
Georgia (20)
Hawaii (2)
Idaho (3)
Illinois (51)
India (37)
Indiana (74)
Japan (255)
Kansas (19)
Kentucky (1)
Louisiana (1)
Maine (4)
Maryland (149)
Massachusetts (1037)
Michigan (21)
Minnesota (51)
Mississippi (1)
Missouri (7)
Nebraska (3)
Nevada (14)
New Hampshire (5)
New Jersey (510)
New York (311)
North Carolina (218)
Northern California (1012)
Ohio (48)
Oklahoma (2)
Oregon (7)
Pennsylvania (222)
Puerto Rico (1)
Rhode Island (4)
South America (148)
South Carolina (1)
Southern California (939)
Tennessee (6)
Texas (206)
United States (5509)
Utah (29)
Virginia (56)
Washington D.C. (6)
Washington State (142)
West Virginia (1)
Wisconsin (20)
109,424 Results for "shenzhen chipscreen biosciences ltd".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
National Medical Products Administration (NMPA) Approves Chipscreen Bioscience’s Chidamide (Epidaza) combined with R-CHOP for the treatment of diffuse large B-cell lymphoma
Shenzhen Chipscreen Biosciences Co., Ltd. announced that the company’s lead innovative product Chidamide, an oral subtype-selective histone deacetylase inhibitor, combined with R-CHOP, has been officially approved by the National Medical Products Administration for treatment of previously untreated diffuse large B-cell lymphoma with positive MYC and BCL2 expression.
April 30, 2024
·
8 min read
Policy
Chipscreen’s New Drug Candidate CS32582 Capsules Approved for Clinical Treatment of Psoriasis
Shenzhen Chipscreen Biosciences Co., Ltd. received the “Drug Clinical Trial Approval Notice” issued by the National Medical Products Administration through its wholly-owned subsidiary, Chengdu Chipscreen Pharmaceutical Co., Ltd.
November 2, 2023
·
4 min read
Business
Biocytogen’s Subsidiary Eucure Biopharma and Chipscreen Biosciences’ Holding Subsidiary Chipscreen NewWay Biosciences Enter into Greater China License Agreement for Bispecific Antibody YH008
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. today announced that its wholly owned subsidiary, Eucure has reached an exclusive licensing agreement with Chipscreen NewWay Biosciences (“Chipscreen NewWay”), a holding subsidiary of Shenzhen Chipscreen Biosciences Co., Ltd. (“Chipscreen Biosciences”, SSE: 688321) for the clinical development and commercialization of bispecific antibody YH008 in Greater China (including Mainland China, Hong Kong, Macau and Taiwan).
February 27, 2023
·
5 min read
Drug Development
Chipscreen Biosciences’ Innovative Anti-Tumor Drug CS231295 Tablets: Investigational New Drug (IND) Application Accepted
October 17, 2024
·
3 min read
Press Releases
QureBio Ltd. to Present at ASCO 2026 its Q-1802 Phase II Clinical Results
January 29, 2026
·
3 min read
Press Releases
Nielsen BioSciences Announces Expanded CANDIN License Agreement with Maruho Co. Ltd.
October 24, 2025
·
3 min read
Drug Development
Positive results from Phase II clinical trial (CGZ203 study) of Chiglitazar monotherapy for non-alcoholic steatohepatitis
On March 18 2024, Shenzhen chipscreen biosciences Co., Ltd. (hereinafter referred to as “chipscreen biosciences”, stock code: 688321. SH) announced that the Phase II clinical trial (CGZ203 study) of chiglitazar monotherapy for non-alcoholic steatohepatitis (NASH) was successfully completed with data cleaning and database locking on February 22, 2024.
March 18, 2024
·
4 min read
Drug Development
Chipscreen NewWay: First Patient Dosed in Phase 1 Trial of the Bispecific Antibody NWY001, a Next-generation Tumor Immunotherapy in Patients with Advanced Solid Tumors
Chengdu Chipscreen NewWay Biosciences Co., Ltd. announced that on January 5, 2024, the dosing of the first patient for a phase I clinical trial of a PD-1/CD40 bispecific antibody, NWY001, at Sun Yat-Sen University Cancer Center in China, the trial-leading institution.
January 16, 2024
·
5 min read
Rational Vaccines and Shenzhen Mellow Hope Pharm Industrial Co., Ltd. Announce Collaboration to Develop Herpes Vaccines in China
Rational Vaccines and Shenzhen Mellow Hope Pharm Industrial Co., Ltd. announced they have reached an agreement to jointly develop, manufacture, and commercialize live vaccines against herpes simplex viruses.
October 30, 2023
·
2 min read
Policy
Licensing Partner of Shenzhen Chipscreen Biosciences - HUYABIO International, Receives Regulatory Approval for Chidamide Monotherapy of Peripheral T-Cell Lymphoma(PTCL) in Japan
Shenzhen Chipscreen Biosciences’ licensing partner, HUYABIO International (HUYABIO™), today announced the regulatory approval for Chidamide (Tucidinostat, also known as Epidaza ®, Hiyasta®, HBI-8000) monotherapy for the treatment of relapsed or refractory (R/R) PTCL by the Ministry of Health, Labour and Welfare in Japan.
December 1, 2021
·
3 min read
1 of 10,943
Next
